In Brief: Circulatory System Devices Panel
This article was originally published in The Gray Sheet
Circulatory System Devices Panel: Premarket approval application for Spectranetics' model 500-001 fiber optic Laser Sheath pacemaker and defibrillator lead removal device slated for review at July 29 meeting at the Holiday Inn in Gaithersburg, Maryland. The Laser Sheath, granted expedited review status by the agency in November 1996, is designed for use with Spectranetics' CVS-300 excimer laser unit to remove pacemaker and implantable cardioverter defibrillator leads by ablating through scar tissue with fiberoptic laser energy. The panel will also be meeting on July 28 to discuss a PMA for PLC Systems' Heart Laser transmyocardial revascularization system ("The Gray Sheet" May 26, In Brief)...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.